Eli Lilly LLY announced positive top-line results from a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, in adults with type II diabetes (T2D) This study, ...

The first study of its kind to compare cardiovascular risk in type 1 diabetes (T1D) and type 2 diabetes (T2D) in both men and women shows that younger men with T2D have worse mortality and ...

Scientists at City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and a leading research center for diabetes and other life-threatening ...

Nearly half of patients with T2D have micronutrient deficiencies, with vitamin D deficiency affecting 60.45% of patients. Women with T2D show a higher prevalence of micronutrient deficiencies compared ...

TORONTO — GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide are well known for helping lower blood sugar and supporting weight loss, as well as reducing the risk for heart and kidney ...

For Jennifer Gowans, a patient ambassador for the American Kidney Fund, helping others is her go-to coping strategy for life with type 2 diabetes and chronic kidney disease. Chronic kidney disease ...

A secondary analysis of the SOUL trial shows significant improvement in heart failure outcomes with oral semaglutide vs placebo, consistent with the injectable formulation.